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ABSTRACT
Using severe combined immunodeficiency mice
engrafted with peripheral blood mononuclear cells
from atopic patients, we analyzed the regulatory
effects of anti-CD154 antibody on the in vivo induc-
tion of human interleukin (IL)-4 and IgE expression.
Although anti-CD154 treatment of engrafted mice
abrogated mature Cε transcription and IgE pro-
duction, IL-4 mRNA levels were enhanced by the
treatment. In addition, anti-CD154-induced enhance-
ment of intracellular IL-4 synthesis was detectable in
both CD4+ and CD8+ T cell subsets. Furthermore,
upregulation of germline Cε transcription could be
seen in anti-CD154-treated mice. These results
demonstrate that blocking the CD154–CD40 inter-
action with anti-CD154 differentially regulates IL-4
synthesis in T cells and IgE production in B cells. Our
data also indicate that antibody ligation of CD154
on T cells causes enhanced synthesis of IL-4, thereby
contributing to upregulation of germline Cε tran-
scription in B cells.
Key words: CD154, CD40, germline Cε, IgE, inter-
leukin-4.
INTRODUCTION
T cell help required for the induction of human IgE syn-
thesis in B cells is mediated through interleukin (IL)-4 or
IL-13 and CD154 provided by activated CD4+ T cells.
Interleukin-4 and IL-13 direct IgE synthesis in B cells by
initiating germline Cε transcription. Such overlapping
effects of IL-4 and IL-13 are brought about by using the
IL-4 receptor α-chain that functions as a common com-
ponent of the receptors of both cytokines.1,2 Ligation of
the counter-receptor for CD154 (i.e. CD40) in conjunc-
tion with the presence of either IL-4 or IL-13 induces IgE
isotype switching in B cells, allowing mature Cε transcrip-
tion and IgE synthesis. Because T cell-dependent B cell
responses, including proliferation, isotype switching and
differentiation, can be blocked by soluble forms of
CD40 or by anti-CD154 antibodies,3,4 the CD154–CD40
interaction is central to the delivery of contact-dependent
T cell help to B cells.
Although signals initiated through the T cell receptor
(TCR)/CD3 complex and CD28 are required for T cell
activation and cytokine production, the role of CD154
expressed on activated T cells in regulating cytokine pro-
duction is poorly understood. Only a few reports have
shown that in vitro costimulation of CD154 with CD40 
on B cells or with an anti-CD154 antibody enhances 
T cell proliferation and Th2 cytokine production.5,6 In
the present study we analyzed the regulatory effects of
anti-CD154 monoclonal antibody (mAb) on the in vivo
expression of both human IL-4 and IgE in severe com-
bined immunodeficiency (SCID) mice engrafted with
peripheral blood mononuclear cells (PBMC) from atopic
patients.
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METHODS
Mice
Female SCID mice (6–7 weeks old) were purchased from
CLEA Japan (Tokyo, Japan). Some leaky mice were elim-
inated by the measurement of serum levels of IgM and
IgG as described previously.7 Non-leaky mice were main-
tained under specific pathogen-free conditions and had
free access to sterilized food and water. All procedures
were performed under a laminar flow hood and con-
ducted according to the guidelines of the National Insti-
tutes of Health Guide for the Care and Use of Laboratory
Animals.
Reconstitution of SCID mice with atopic
human PBMC
Peripheral blood mononuclear cells were isolated from
the heparinized venous blood of atopic patients allergic
to house dust mites by density gradient sedimentation, as
described previously.8 Based on preliminary studies using
SCID mice inoculated intraperitoneally with 3 × 107 cells
suspended in 0.5 mL Hanks’ balanced salt solution (HBSS),
PBMC from three patients were selected to cause IgE pro-
duction and were used in this study. The patients’ serum
IgE levels were 473, 810 and 3740 IU/mL. The donors
used for collection of peripheral blood gave informed
consent to participate in the study.
Collection of blood and preparation of 
peritoneal lavage cells from SCID mice
Severe combined immunodeficiency mice reconstituted
with atopic human PBMC were bled retro-orbitally at a
weeks interval. Serum levels of human IgE and IgG were
measured by isotype-specific sandwich radioimmuno-
assays, as described previously.9 Peritoneal washings
were harvested 0–7 days postengraftment from the mice
by injecting 5 mL cold HBSS. Phenotypic analysis showed
that approximately 50% of the peritoneal lavage cells was
of human origin immediately after PBMC transfer and this
ratio gradually decreased afterwards.
Antibodies used for in vivo treatment of SCID
mice
Mouse antihuman CD154 mAb (IgG1), which inhibits
the binding of CD154 to CD40, was obtained from
Ancell (Bayport, MN, USA) and purified myeloma mouse
IgG1 (control antibody) was from Cappel (West Chester,
PA, USA). Either anti-CD154 mAb or control anti-
body (100 µg/animal per day) was administered intra-
peritoneally to reconstituted SCID mice for up to 5 days.
Reverse transcription–polymerase chain 
reaction analysis
Extraction of total cellular RNA, cDNA synthesis by
reverse transcription (RT) and polymerase chain reaction
(PCR) were performed exactly as described previously.9
The 5′ sense primers and 3′ antisense primers used for
the amplification of mRNA for human IL-4, germline Cε
and mature Cε in peritoneal lavage cells from reconsti-
tuted SCID mice were the same as described previously.9,10
Primers pairs specific for human β-actin were obtained
from Clontech Laboratories (Palo Alto, CA, USA). For
semiquantitative PCR analysis, total cellular RNA, which
contains both murine and human RNA, was serially
diluted and each dilution was applied to PCR. The PCR
products were separated on a 2% agarose gel and
stained with ethidium bromide. Polymerase chain reac-
tion blots were quantitated by scanning with a GS-700
imaging densitometer (Bio-Rad Laboratories, Hercules,
CA, USA). The β-actin amplification product obtained
from each RNA sample (100 ng) was used as an external
standard and the amount of each amplification product
was evaluated as the ratio of IL-4, germline Cε or mature
Cε mRNA : β-actin mRNA × 100.
Flow cytometric analysis
Surface expression of human αβ TCR, CD4, CD8 and
CD45 and murine H-2Kd on peritoneal lavage cells from
reconstituted SCID mice was analyzed by flow cytometry
as described previously.7 Detection of intracellular human
IL-4 was performed by using a commercially available
intracellular staining kit (Becton Dickinson, San Jose, CA,
USA). Briefly, cells were incubated with fluorescein iso-
thiocyanate (FITC)- or biotin-labeled mouse mAbs to
human αβ TCR, CD4, CD8 or CD45, phycoerythrin 
(PE)-labeled rat mAb to murine H-2Kd or FITC-labeled
streptoavidin (in the case of biotin-labeled mAbs) fol-
lowed by fixation with 4% paraformaldehyde and
incubation with permeabilizing solution containing 0.1%
saponin. After washing, cells were incubated with a 
PE-labeled mouse mAb to human IL-4 to stain intra-
cellular IL-4. Isotype-matched control mAbs were used
for negative staining. The mAbs to αβ TCR, CD4, CD8
and CD45 were obtained from Becton Dickinson and
anti-H-2Kd mAb was from PharMingen (San Diego, CA,
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USA). Stained cells were analyzed by a FACScan (Becton
Dickinson) using a gate for human CD45+ cells. Fluor-
escence data were collected by using logarithmic
amplification.
RESULTS
SCID mice engrafted with atopic human PBMC were
treated intraperitoneally for 5 days with anti-CD154 mAb
or with phosphate-buffered saline (PBS) or with an
isotype-matched control antibody. The serum levels of
human IgE and IgG were then determined in the mice at
a weeks interval over a 4 week period. As shown in Fig. 1,
the IgE levels of control mice treated with PBS started to
increase as early as 1 week after PBMC transfer, reached
a maximum at 2 weeks and declined thereafter, while the
IgG concentrations increased gradually after the graft.
Treatment with anti-CD154, but not with control anti-
body, abrogated both IgE and IgG production, which was
expected because the CD154–CD40 interaction in the
presence of cytokines is required for the induction of
isotype switching to IgE or IgG.3,4
To evaluate the effects of anti-CD154 treatment on the
expression of mRNA for human IL-4, germline Cε and
mature Cε, peritoneal lavage cells were harvested 0.5, 1,
3 and 5 days postengraftment from mice treated with
control antibody or with anti-CD154 for up to 5 days and
were analyzed by semiquantitative RT-PCR (Fig. 2). Table 1
summarizes the results obtained in three separate experi-
ments using mice engrafted with three different PBMC. In
control mice, IL-4 mRNA expression rose rapidly and
reached peak levels between 1 and 3 days after PBMC
transfer and both germline and mature Cε transcripts
gradually accumulated afterwards. In mice treated with
anti-CD154, IL-4 and germline Cε mRNA levels were sig-
nificantly increased 5.1-fold (1 day after cell transfer) and
10.2-fold (3 days after the graft), respectively, compared
with those of the controls. Nevertheless, mature Cε tran-
scripts were hardly detectable, even after 3–5 days
treatment with anti-CD154.
On the basis of the observation that anti-CD154 treat-
ment led to increased expression of IL-4 mRNA, we
further examined intracellular expression of IL-4 by
human T cells in peritoneal washings from mice treated
with control antibody or with anti-CD154 for up to 5 days.
To determine the kinetics of human IL-4 synthesis in
PBMC-injected mice, peritoneal lavage cells were recov-
ered 1, 3, 5 and 7 days postengraftment from mice and
were analyzed by flow cytometry using mAbs to human 
IL-4 and T cell surface markers. Figure 3 shows a rep-
resentative time-course of human IL-4 synthesis in control
and anti-CD154-treated mice. The peak of intracellular
IL-4 synthesis in human αβ T cells from control mice was
observed between 3 and 5 days after PBMC transfer.
Analysis of human CD4+ and CD8+ cell subsets gave
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Fig. 1 Effects of anti-CD154 monoclonal antibody (mAb) on
human (a) IgE and (b) IgG production in severe combined
immunodeficiency mice engrafted with peripheral blood
mononuclear cells (PBMC) from an atopic patient. Engrafted
mice were treated for 5 days with phosphate-buffered saline
(), control antibody () or anti-CD154 mAb (). After being
bled at the indicated times, serum levels of human IgE and IgG
were measured. Results are the mean ± SEM of five mice.
Similar results were obtained when PBMC from two other
atopic patients were used.
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Fig. 2 Effects of anti-CD154 monoclonal antibody (mAb) on the expression of mRNA for human interleukin (IL)-4, germline Cε
and mature Cε in severe combined immunodeficiency mice engrafted with atopic human peripheral blood mononuclear cells
(PBMC). Peritoneal lavage cells were harvested at the indicated times from mice treated with control antibody or with anti-CD154
mAb for up to 5 days. After extraction and serial dilution of total cellular RNA, the expression of mRNA for human IL-4, germline Cε,
mature Cε and β-actin was analyzed by semiquantitative reverse transcription–polymerase chain reaction.
Table 1 Effects of anti-CD154 monoclonal antibody on the expression of mRNA for human interleukin-4, germline Cε and
mature Cε in severe combined immunodeficiency mice engrafted with atopic human peripheral blood mononuclear cells
Treatment mRNA Days after cell transfer
0.5 1 3 5
Control antibody IL-4 3.8 ± 1.6 8.2 ± 2.4 9.6 ± 2.7 6.2 ± 2.3
Germline Cε 4.5 ± 1.2 6.1 ± 2.8 10.5 ± 3.2 24.0 ± 5.2
Mature Cε 1.2 ± 0.3 9.5 ± 2.1 18.8 ± 3.4 25.7 ± 4.9
Anti-CD154 mAb IL-4 15.3 ± 2.5* 42.0 ± 6.6** 31.2 ± 4.7** 24.8 ± 5.9*
Germline Cε 23.9 ± 4.1** 51.9 ± 9.8** 107.6 ± 8.2** 115.1 ± 12.4**
Mature Cε < 0.1** < 0.1*** < 0.1*** < 0.1***
Peritoneal lavage cells were harvested 0.5–5 days postengraftment from mice treated with control antibody or with anti-CD154 monoclonal anti-
body (mAb) for up to 5 days. After extraction of total cellular RNA, mRNA for human interleukin (IL)-4, germline Cε and mature Cε were amplified by
reverse transcription–polymerase chain reaction (RT-PCR) and the PCR products were quantified by a densitometer. The amount of each amplifica-
tion product was evaluated as the ratio of IL-4 or Cε mRNA : β-actin mRNA × 100.
Results are expressed as the mean ± SEM of three separate experiments, each performed in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001
compared with control antibody treated mice (Mann–Whitney U-test).
similar results. In mice treated with anti-CD154, IL-4
synthesis by human αβ T cells was rapid compared with
the controls and reached a maximum between 1 and 3
days after PBMC transfer. In addition, fluorescence inten-
sity for intracellular IL-4 was markedly enhanced by
anti-CD154 treatment. The effect was observed in
human CD4+ as well as in CD8+ T cells, although it was
more evident in CD4+ T cells.
DISCUSSION
In the present study, we investigated the effect of anti-
CD154 administration on human IL-4 synthesis and on
IgE production in SCID mice engrafted with atopic human
PBMC in order to assess some of the immunologic mech-
anisms involved in the CD154–CD40 interaction. We
found that anti-CD154 treatment of engrafted mice
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Fig. 3 Effects of anti-CD154 monoclonal antibody (mAb) on the intracellular expression of human interleukin (IL)-4 in severe
combined immunodeficiency mice engrafted with atopic human peripheral blood mononuclear cells (PBMC). Peritoneal lavage
cells were harvested at the indicated times from mice treated with control antibody or with anti-CD154 mAb for up to 5 days.
Cells were incubated with fluorescein isothiocyanate-labeled antihuman CD4 or CD8 mAbs, fixed in paraformaldehyde, per-
meabilized with saponin, and then stained with a phycoerythrin (PE)-labeled antihuman IL-4 mAb. In each experiment,
background staining was obtained by incubating cells with isotype-matched control mAbs. Stained cells were analyzed by flow
cytometry.
greatly enhanced expression of IL-4 mRNA and protein in
T cells, thereby contributing to upregulation of germline
Cε transcription in B cells. In contrast, mature Cε tran-
scription and IgE production were abrogated by the
treatment, in accordance with expectations. These results
confirm, in part, some of the previously published
data3–6,11,12 and demonstrate that blocking the CD154–
CD40 interaction with anti-CD154 differentially regu-
lates IL-4 synthesis in T cells and IgE production in B cells.
The enhancement of IL-4 synthesis observed in T cells
from anti-CD154-treated mice is in keeping with a pre-
vious study describing that IL-4 synthesis in CD4+ T cells
was enhanced by triggering of CD154 in conjunction
with ligation of CD3 and CD28.6 However, in this in vitro
study6 it was not examined whether costimulation of
CD154 on CD8+ T cells could enhance IL-4 synthesis.
Intracellular staining of IL-4 synthesis in our in vivo exper-
iments revealed that upregulation of IL-4 synthesis by
anti-CD154 treatment was inducible in CD4+ and CD8+
T cells. The enhanced induction of IL-4 synthesis in these
two T cell subsets necessarily requires their surface
expression of CD154. In this context, we reported that
CD154 expression was found on human CD4+ as well 
as on CD8+ T cells after reconstitution of SCID mice 
with atopic human PBMC.7 To our knowledge, CD154-
mediated enhancement of IL-4 synthesis in CD8+ T cells
has not been previously demonstrated both in vitro and 
in vivo. Although CD154 engagement has been shown to
play an accessory role in the regulation of CD4+ T cell
function and cytokine production,5,6,11,12 our data showed
that CD8+ T cells, like CD4+ T cells, can be primed to
enhance IL-4 synthesis through triggering of CD154.
These findings indicate that CD154 ligation plays an
important role in the regulation of IL-4 synthesis in T cells,
including CD4+ and CD8+ subsets.
We also demonstrated that germline Cε transcription
was markedly enhanced in anti-CD154-treated mice.
This could be most likely due to the enhanced IL-4 syn-
thesis that resulted from antibody ligation of CD154 on
CD4+ and CD8+ T cell subsets. Actually, enhancement of
IL-4 synthesis by anti-CD154 treatment correlated well
with upregulation of germline Cε transcription. Because
both IL-4 and IL-13 contribute to the induction of germ-
line Cε transcripts, the possibility of the participation 
of IL-13 in the regulation of germline Cε transcription
cannot be ruled out. In our SCID mouse model, the peak
of IL-4 mRNA expression was observed between 1 and 
3 days after PBMC transfer, whereas IL-13 mRNA started
to accumulate at 5 days after the graft (data not shown).
Interestingly, the upregulation of germline Cε transcription
in anti-CD154-treated mice could be seen before IL-13
mRNA induction, which suggested that IL-4, but not IL-13,
was a contributing factor to increased germline Cε tran-
scription. However, it remains to be determined whether
CD154 ligation regulates IL-13 synthesis in CD4+ and in
CD8+ T cells.
In summary, we have shown that anti-CD154 treatment
of atopic human PBMC-injected SCID mice upregulates
germline Cε transcription in B cells by potentiating IL-4
synthesis in CD4+ and CD8+ T cell subsets, despite
inevitable abrogation of mature Cε transcription and IgE
production. Thus, blocking the CD154–CD40 interaction
with anti-CD154 allows reciprocal regulation of germline
and mature Cε transcription. While numerous studies
have shown that ligation of CD40 on B cells is critical for
immunoglobulin class switching,13–15 the major finding 
in the present study is that in vivo triggering of CD154 
on T cells functions as a costimulus for IL-4 synthesis in
CD4+ T cells as well as in CD8+ T cells. Our data support
the notion that CD154–CD40 interactions are critically
involved in the regulation of T and B cell function.
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